Research graph
References from Targeting SYK enhances responses to radiotherapy and PD-1 blockade with myeloid immune remodeling in breast cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
The SYK tyrosine kinase: a crucial player in diverse biological functions
10.1038/nri2765 · 2010 · External reference
SYK as a new therapeutic target in B-cell precursor acute lymphoblastic leukemia
10.4236/jct.2014.51015 · 2014 · External reference
Discovery and development of spleen tyrosine kinase (SYK) inhibitors
10.1021/jm201271b · 2012 · External reference
Inflammatory signaling pathways play a role in SYK inhibitor resistant AML
10.1038/s41598-025-96660-w · 2025 · External reference
New insights into SYK targeting in solid tumors
10.1016/j.tips.2024.08.006 · 2024 · External reference
The Syk tyrosine kinase suppresses Malignant growth of human breast cancer cells
10.1038/35021086 · 2000 · External reference
Hypermethylation and prognostic implication of Syk gene in human colorectal cancer
10.1007/s12032-013-0586-8 · 2013 · External reference
Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion
10.2353/ajpath.2009.090543 · 2009 · External reference
Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer
10.1186/1752-0509-7-s5-s1 · 2013 · External reference
B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas
10.1016/j.ccr.2014.04.026 · 2014 · External reference
Macrophage Syk-PI3Kγ inhibits antitumor immunity: SRX3207, a novel dual Syk-PI3K inhibitory chemotype relieves tumor immunosuppression
10.1158/1535-7163.mct-19-0947 · 2020 · External reference
Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma
10.1158/0008-5472.can-22-3645 · 2023 · External reference
Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19
10.1126/sciadv.ade8272 · 2023 · External reference
Triple negative breast cancer: Pitfalls and progress
10.1038/s41523-022-00468-0 · 2022 · External reference
Less isn't simple: Insights from postmastectomy radiotherapy deintensification trials
10.1200/jco-25-02852 · 2026 · External reference
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
10.1016/s1470-2045(21)00589-1 · 2022 · External reference
Enhancing radiotherapy techniques for triple-negative breast cancer treatment
10.1016/j.ctrv.2025.102939 · 2025 · External reference
Radiation-induced tumor immune microenvironments and potential targets for combination therapy
10.1038/s41392-023-01462-z · 2023 · External reference
Tumour-associated macrophages as treatment targets in oncology
10.1038/nrclinonc.2016.217 · 2017 · External reference
Functional roles of Syk in macrophage-mediated inflammatory responses
10.1155/2014/270302 · 2014 · External reference
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
10.1016/s1470-2045(15)00007-8 · 2015 · External reference
Macrophage diversity enhances tumor progression and metastasis
10.1016/j.cell.2010.03.014 · 2010 · External reference
Macrophages and therapeutic resistance in cancer
10.1016/j.ccell.2015.02.015 · 2015 · External reference
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation
10.1124/jpet.106.109058 · 2006 · External reference
Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation
10.1124/dmd.110.032151 · 2010 · External reference
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
10.1038/ncomms11479 · 2016 · External reference
Cytotoxic lymphocyte-related gene signature in triple-negative breast cancer
10.3390/jpm13030457 · 2023 · External reference
TIMER2.0 for analysis of tumor-infiltrating immune cells
10.1093/nar/gkaa407 · 2020 · External reference
TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells
10.1158/0008-5472.can-17-0307 · 2017 · External reference
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
10.1186/s13059-016-1028-7 · 2016 · External reference
Stromal cell diversity associated with immune evasion in human triple-negative breast cancer
10.15252/embj.2019104063 · 2020 · External reference
A human breast atlas integrating single-cell proteomics and transcriptomics
10.1016/j.devcel.2022.05.003 · 2022 · External reference
TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues
10.3390/ijms22052622 · 2021 · External reference
Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy
10.1016/j.drup.2024.101085 · 2024 · External reference
Molecular and cellular insights into T cell exhaustion
10.1038/nri3862 · 2015 · External reference
Primary, adaptive, and acquired resistance to cancer immunotherapy
10.1016/j.cell.2017.01.017 · 2017 · External reference
NF-κB in monocytes and macrophages - an inflammatory master regulator in multitalented immune cells
10.3389/fimmu.2023.1134661 · 2023 · External reference
Macrophage polarization in chronic inflammatory diseases: killers or builders
10.1155/2018/8917804 · 2018 · External reference
Tumor-associated macrophages are associated with response to neoadjuvant chemotherapy and poor outcomes in patients with triple-negative breast cancer
10.7150/jca.47566 · 2021 · External reference
Tumor-associated macrophages in radiotherapy: mechanisms of polarization, immune regulation and therapeutic strategies
10.1016/j.intimp.2025.115009 · 2025 · External reference
Event-free survival with pembrolizumab in early triple-negative breast cancer
10.1056/nejmoa2112651 · 2022 · External reference
Overall survival with pembrolizumab in early-stage triple-negative breast cancer
10.1056/nejmoa2409932 · 2024 · External reference
Tumor-associated macrophages: from mechanisms to therapy
10.1016/j.immuni.2014.09.021 · 2014 · External reference
FDA approves first-in-class SYK inhibitor
10.1038/nrd.2018.96 · 2018 · External reference
Hypermethylation and prognostic implication of Syk gene in human colorectal cancer
10.1007/s12032-013-0586-8 · ExternalCitation · doi-reference
Macrophages and therapeutic resistance in cancer
10.1016/j.ccell.2015.02.015 · ExternalCitation · doi-reference
B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas
10.1016/j.ccr.2014.04.026 · ExternalCitation · doi-reference
Macrophage diversity enhances tumor progression and metastasis
10.1016/j.cell.2010.03.014 · ExternalCitation · doi-reference
Primary, adaptive, and acquired resistance to cancer immunotherapy
10.1016/j.cell.2017.01.017 · ExternalCitation · doi-reference
Enhancing radiotherapy techniques for triple-negative breast cancer treatment
10.1016/j.ctrv.2025.102939 · ExternalCitation · doi-reference
A human breast atlas integrating single-cell proteomics and transcriptomics
10.1016/j.devcel.2022.05.003 · ExternalCitation · doi-reference
Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy
10.1016/j.drup.2024.101085 · ExternalCitation · doi-reference
Tumor-associated macrophages: from mechanisms to therapy
10.1016/j.immuni.2014.09.021 · ExternalCitation · doi-reference
Tumor-associated macrophages in radiotherapy: mechanisms of polarization, immune regulation and therapeutic strategies
10.1016/j.intimp.2025.115009 · ExternalCitation · doi-reference
New insights into SYK targeting in solid tumors
10.1016/j.tips.2024.08.006 · ExternalCitation · doi-reference
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
10.1016/s1470-2045(15)00007-8 · ExternalCitation · doi-reference
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
10.1016/s1470-2045(21)00589-1 · ExternalCitation · doi-reference
Discovery and development of spleen tyrosine kinase (SYK) inhibitors
10.1021/jm201271b · ExternalCitation · doi-reference
The Syk tyrosine kinase suppresses Malignant growth of human breast cancer cells
10.1038/35021086 · ExternalCitation · doi-reference
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
10.1038/ncomms11479 · ExternalCitation · doi-reference
Tumour-associated macrophages as treatment targets in oncology
10.1038/nrclinonc.2016.217 · ExternalCitation · doi-reference
FDA approves first-in-class SYK inhibitor
10.1038/nrd.2018.96 · ExternalCitation · doi-reference
The SYK tyrosine kinase: a crucial player in diverse biological functions
10.1038/nri2765 · ExternalCitation · doi-reference
Molecular and cellular insights into T cell exhaustion
10.1038/nri3862 · ExternalCitation · doi-reference
Radiation-induced tumor immune microenvironments and potential targets for combination therapy
10.1038/s41392-023-01462-z · ExternalCitation · doi-reference
Triple negative breast cancer: Pitfalls and progress
10.1038/s41523-022-00468-0 · ExternalCitation · doi-reference
Inflammatory signaling pathways play a role in SYK inhibitor resistant AML
10.1038/s41598-025-96660-w · ExternalCitation · doi-reference
Event-free survival with pembrolizumab in early triple-negative breast cancer
10.1056/nejmoa2112651 · ExternalCitation · doi-reference
Overall survival with pembrolizumab in early-stage triple-negative breast cancer
10.1056/nejmoa2409932 · ExternalCitation · doi-reference
TIMER2.0 for analysis of tumor-infiltrating immune cells
10.1093/nar/gkaa407 · ExternalCitation · doi-reference
Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation
10.1124/dmd.110.032151 · ExternalCitation · doi-reference
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation
10.1124/jpet.106.109058 · ExternalCitation · doi-reference
Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19
10.1126/sciadv.ade8272 · ExternalCitation · doi-reference
Functional roles of Syk in macrophage-mediated inflammatory responses
10.1155/2014/270302 · ExternalCitation · doi-reference
Macrophage polarization in chronic inflammatory diseases: killers or builders
10.1155/2018/8917804 · ExternalCitation · doi-reference
TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells
10.1158/0008-5472.can-17-0307 · ExternalCitation · doi-reference
Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma
10.1158/0008-5472.can-22-3645 · ExternalCitation · doi-reference
Macrophage Syk-PI3Kγ inhibits antitumor immunity: SRX3207, a novel dual Syk-PI3K inhibitory chemotype relieves tumor immunosuppression
10.1158/1535-7163.mct-19-0947 · ExternalCitation · doi-reference
Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer
10.1186/1752-0509-7-s5-s1 · ExternalCitation · doi-reference
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
10.1186/s13059-016-1028-7 · ExternalCitation · doi-reference
Less isn't simple: Insights from postmastectomy radiotherapy deintensification trials
10.1200/jco-25-02852 · ExternalCitation · doi-reference
Stromal cell diversity associated with immune evasion in human triple-negative breast cancer
10.15252/embj.2019104063 · ExternalCitation · doi-reference
Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion
10.2353/ajpath.2009.090543 · ExternalCitation · doi-reference
NF-κB in monocytes and macrophages - an inflammatory master regulator in multitalented immune cells
10.3389/fimmu.2023.1134661 · ExternalCitation · doi-reference
TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues
10.3390/ijms22052622 · ExternalCitation · doi-reference
Cytotoxic lymphocyte-related gene signature in triple-negative breast cancer
10.3390/jpm13030457 · ExternalCitation · doi-reference
SYK as a new therapeutic target in B-cell precursor acute lymphoblastic leukemia
10.4236/jct.2014.51015 · ExternalCitation · doi-reference
Tumor-associated macrophages are associated with response to neoadjuvant chemotherapy and poor outcomes in patients with triple-negative breast cancer
10.7150/jca.47566 · ExternalCitation · doi-reference
